Active Biotech AB, of Lund, Sweden, and Ipsen SA, of Paris, said they started a Phase II proof-of-concept study testing tasquinimod in advanced metastatic castrate-resistant prostate cancer (CRPC

NewLink Genetics Inc., of Ames, Iowa, said it will start a Phase II study testing its IDO pathway inhibitor, indoximod (D-1MT/NLG8189), in combination with Provenge (sipuleucel-T) in patients with asymptomatic or minimally symptomatic metastatic hormone-refractory prostate cancer

Senesco Technologies Inc., of Bridgewater, N.J., said the first patient was enrolled and dosing has begun in the second cohort of its study testing SNS01-T in multiple myeloma

Oncolytics Biotech Inc., of Calgary, Alberta, said it conducted an internal analysis of the blinded combined data for all 80 patients enrolled in the first stage of its Phase III study testing oncolytic virus Reolysin in combination with carboplatin and paclitaxel for the treatment of head and neck cancers, with data showing a greater than expected median evolving progression-free survival (PFS) of the 80 patients, which comprise the combined control and test groups...Santarus Inc., of San Diego

Palatin Technologies Inc., of Cranbury, N.J., said the last patient completed treatment in its Phase IIb study testing melanocortin agonist bremelanotide in female sexual dysfunction, and top-line data are expected in the first half of next quarter

Additionally, the firm reported, a recently completed Phase II study testing the drug as an adjunctive treatment with atypical antipsychotics did not meet its primary endpoint

America Stem Cell Inc., of San Antonio, said it started a single-center study testing ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies

Evolva Holdings SA, of Reinach, Switzerland, said top-line results for the first 32 patients enrolled in the Phase IIa study testing EV-077, a reversible antagonist of isoprostanes and prostanoids, showed promising efficacy, indicating that the drug, when given orally twice daily to patients with Type II diabetes, provided antiplatelet activity, reduced exercise-induced proteinuria and increased forearm blood flow

The study is expected to enroll about 240 patients undergoing cataract surgery in a two-arm study testing BromSite against the DuraSite vehicle alone...Pharmacyclics Inc., of Sunnyvale, Calif., said its Phase III RESONATE study testing ibrutinib vs. Arzerra (ofatumumab, Gemnab A/S and GlaxoSmithKline plc) enrolled its fifth patient, triggering a $50 million milestone from partner Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson

Cerulean Pharma Inc., of Cambridge, Mass., said it dosed the first patient in a Phase II study testing CRLX101 in platinum-resistant ovarian cancer...Chimerix Inc., of Research Triangle Park, N.C., said BK virus (BKV) data from a Phase II study testing CMX001 vs

AMAG Pharmaceuticals Inc., of Lexington, Mass., reported preliminary results from the second Phase III study testing Feraheme (ferumoxytol) in patients with iron deficiency anemia regardless of the underlying cause

Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said it completed enrollment in Study NX02-0020, one of its Phase III studies testing NX-1207 in benign prostatic hyperplasia

Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said the first patients were treated in a Phase I study testing immune responses in elderly subjects immunized with the firm's H1N1 SynCon universal influenza vaccine

Ultragenyx Pharmaceutical Inc., of Novato, Calif., said it dosed the first two patients in a Phase II study testing UX001 in hereditary inclusion body myopathy (HIBM), a rare neuromuscular disease caused by sialic acid deficiency

OncoSec Medical Inc., of San Diego, said its Phase II study testing plasmid interleukin-12 (DNA IL-12) with electroporation has completed about 50 percent of enrollment, with no Grade 3 or higher adverse events related to treatment reported

Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said it enrolled the first patient for Study NX03-0040, a Phase II study testing NX-1207 in low risk localized prostate cancer

Celgene Corp., of Summit, N.J., said it completed enrollment in a Phase III study testing Abraxane (paclitaxel protein-bound particles for injectable suspension) in metastatic pancreatic cancer, with 861 patients randomized to receive Abraxane plus gemcitabine vs

Spectrum Pharmaceuticals Inc., of Henderson, Nev., said it started patient enrollment in a Phase I study testing RenaZorb (SPI-014), a lanthanum-based nanotechnology compound with phosphate-binding properties, in healthy volunteers

Diamyd Medical AB, of Stockholm, Sweden, said it completed enrollment in its Phase II study testing NP2 Enkephalin in cancer pain